Related Experiment Video
Updated: Feb 15, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need
Giuseppe Santarpia1, Salvatore De Rosa1, Jolanda Sabatino1
1Division of Cardiology, Department of Medical and Surgical Sciences, Magna Græcia University, Catanzaro, Italy.
Insights
Prolonged oral anticoagulation therapy after radiofrequency catheter ablation for atrial fibrillation (AF) did not significantly reduce thromboembolic events but increased bleeding risk. Further trials are needed to determine the net clinical benefit of continuing anticoagulation post-ablation.
Area of Science:
- Cardiology
- Clinical Medicine
- Evidence-Based Medicine
Background:
- Atrial fibrillation (AF) increases stroke risk, often managed with oral anticoagulation therapy (OAT).
- Radiofrequency catheter ablation (RFCA) is a treatment for AF, but the role of continued OAT post-procedure remains unclear.
- The net clinical benefit of prolonged OAT after successful RFCA requires further investigation.
Purpose of the Study:
- To evaluate the clinical significance of continuing OAT versus no OAT in AF patients post-successful RFCA.
- To assess the impact of OAT on thromboembolic and bleeding events after RFCA.
Main Methods:
- A meta-analysis of scientific investigations comparing OAT versus no OAT in AF patients undergoing successful RFCA.
- Odds ratios (OR) with 95% confidence intervals (CI) were used as summary measures.
- Studies assessed the clinical significance of anticoagulation strategies.
Main Results:
- Meta-analysis showed no significant difference in total thromboembolic events between OAT and no OAT groups (OR 1.83, 95% CI 0.69-4.88; p=0.221).
- A significantly lower incidence of total bleeding events was observed in patients not treated with OAT (OR 6.5, 95% CI 1.93-21.86; p=0.002).
Conclusions:
- Long-term prophylactic OAT after successful RFCA for AF may not offer a net clinical benefit.
- Increased bleeding risk with OAT suggests caution in its continuation post-RFCA.
- The lack of prospective randomized trials necessitates a new trial to fully assess the net clinical benefit of prolonged OAT after RFCA.
Background:
Atrial fibrillation (AF) is associated with a high risk of thromboembolic stroke and oral anticoagulation therapy (OAT) is able to reduce the rate of ischemic events. Nevertheless, the actual benefit of prolonged OAT after successful radiofrequency catheter ablation (RFCA) is not clear yet.
Methods:
Scientific investigations were assumed suitable if they assessed the clinical significance of the use of anticoagulation versus no anticoagulation in AF patients undergoing successful RFCA. The odds ratio (OR) with 95% confidence interval (CI) was used as the study summary measure.
Results:
At meta-analysis, the rate of total thromboembolic events was not significantly different between the groups (OR 1.83, 95% CI 0.69-4.88; p = 0.221), while a lower incidence of total bleeding events in patients not treated with OAT was found (OR 6.5, 95% CI 1.93-21.86; p = 0.002).
Conclusion:
This meta-analysis raises doubts about the net clinical benefit (NCB) of a long-term prophylactic OAT in patients with AF underwent to successful RFCA. In fact, despite similar rate of thromboembolic events, the apparent increase in bleeding risk suggests caution in prolonging OAT after RFCA. However, the lack of prospective randomized studies does not allow a comprehensive appraisal of this issue. Thus, we propose the design of a novel prospective randomized trial to evaluate the NCB of prolonged OAT after successful RFCA of AF.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
02:17Ecological Succession
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
01:11Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...